H.C. Wainwright Reiterates Buy Rating on Lava Therapeutics NV (LVTX)

H.C. Wainwright analyst Arthur He reiterated a Buy rating and $6.00 price target on Lava Therapeutics NV (NASDAQ: LVTX).

The analyst commented: "On June 25, LAVA attended our 2nd Annual Immune Cell Engager Conference, and we had a fireside chat with the management. During our conversation, management reiterated their plan to present additional clinical data from the Phase 1/2a study evaluating LAVA-1207 for the treatment refractory metastatic castration-resistant prostate cancer (mCRPC) at a medical conference in 2H24. To date, the monotherapy arm of the study has completed enrollment in the dose level 10 (DL10), and now is enrolling patients in DL11. Management believe DL10 and DL11 are in the range of biologically active dose levels for the drug. We maintain our Buy rating on LVTX and 12-month price target of $6 per share."

For an analyst ratings summary and ratings history on Lava Therapeutics NV click here. For more ratings news on Lava Therapeutics NV click here.

Shares of Lava Therapeutics NV closed at $1.88 yesterday.

You May Also Be Interested In

• Stripe, Advent In Talks To Buy Paypal - WSJ
• Full Circle Lithium closes $5.14M private placement
• AI/ML Innovations plans $2M private placement on the CSE